China Biologic Products, Inc. News
China Biologic Products Announces the Change of CEO and CFO
TAIAN CITY,
On
Mr. Zhao has been CBP's Director since
Mr. Kuo has more than 27 years of accounting, finance and information systems work experience in manufacturing, commodity trading and banking industries where he has served in the capacity of CFO, CIO and Controller. Of these years, Mr. Kuo worked for 25 years in the U.S. and for 2 years in
"We highly value Mr. Wong's contribution to our company in the past and his assistance in effecting a smooth transaction," said Mr. Zhao. "We are also pleased that Mr. Kuo has agreed to serve as the Company's CFO. We expect that his in-depth finance experience and his background in the U.S. capital market will inform our operations and business strategies and make him a valuable member of our team."
On
About China Biologic Products, Inc.
Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the effect of the new management on the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward- looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For more information, please contact: Company Contact: Mr. Stanley Wong CEO China Biologic Products, Inc. Tel: +86-538-620-2306 Email: IR@chinabiologic.com Web: http://www.chinabiologic.com Investor Relations Contact: Mr. Crocker Coulson President CCG Elite Investor Relations Tel: +1-646-213-1915 (NY office) Email: crocker.coulson@ccgir.com Web: http://www.ccgelite.com
SOURCE China Biologic Products, Inc.
Search Our News Using Google Search
Can't find what you want? Try using Google:



